Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT03848923 · ClinicalTrials.gov registry record
Impact of Thrombocytopenia and Platelet Transfusions on Neonatal Bleeding and Inflammation
A clinical trial of Neonatal Thrombocytopenia, sponsored by Boston Children's Hospital.
- Recruiting
- Registry status
- 160
- Enrollment target
- 2
- Study locations
NCT03848923: Recruiting study of Neonatal Thrombocytopenia, sponsored by Boston Children's Hospital.
NCT03848923 is a study of Neonatal Thrombocytopenia that is actively recruiting participants, run by Boston Children's Hospital. The registered enrollment target is 160 participants. The trial reports 2 study locations across 1 state. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT03848923, a study of Neonatal Thrombocytopenia, is actively recruiting participants, sponsored by Boston Children's Hospital.
- RECRUITING
- Registry status
- 160 participants
- Enrollment target
- 2
- Study locations
Study Summary
This is a prospective observational study that was designed with the following two Specific Aims: 1. To determine whether the Immature Platelet Fraction percentage (IPF%) and the Immature Platelet Count (IPC) are better predictors of bleeding than the platelet count alone in neonates of different gestational and post-conceptional ages and with different etiologies of thrombocytopenia; and 2. To characterize the effects of neonatal thrombocytopenia and platelet transfusions (PLT Tx) on bleeding and on markers of systemic inflammation, thrombosis, and neutrophil extracellular traps (NET) formation in neonates with different underlying conditions.
Conditions Studied
Study Locations (2)
Massachusetts
- Beth Israel Deaconess Medical Center - Boston
- Boston Children's Hospital - Boston
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 160 participants |
| Start Date | 2019-08-19 |
| Est. Completion | 2026-09-01 |
What NCT03848923 shows while recruiting
NCT03848923 is an observational study that tracks outcomes without assigning an intervention. The registered 160 participants enrollment target is mid-sized for trials with a published cap.
The record links to 1 condition, with Neonatal Thrombocytopenia appearing as the primary indexed condition, and to 0 interventions.
NCT03848923 reports a single indexed study location in Massachusetts.
Frequently Asked Questions
What is clinical trial NCT03848923 about?
NCT03848923 is a clinical study titled "Impact of Thrombocytopenia and Platelet Transfusions on Neonatal Bleeding and Inflammation". This is a prospective observational study that was designed with the following two Specific Aims: 1. To determine whether the Immature Platelet Fraction percentage (IPF%) and the Immature Platelet Count (IPC) are better predictors of bleeding than the platelet count alone in neonates of different g...
What is the current status of trial NCT03848923?
This trial is currently recruiting. The enrollment target is 160 participants. The study started on 2019-08-19. Estimated completion is 2026-09-01.
What conditions does trial NCT03848923 study?
This clinical trial studies the following conditions: Neonatal Thrombocytopenia.
Who is sponsoring clinical trial NCT03848923?
This trial is sponsored by Boston Children's Hospital, which has 462 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT03848923 being conducted?
This trial has 2 study locations across Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Neonatal Thrombocytopenia
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT00501826 · 160 participants · Phase 2
Combination Chemotherapy and Nelarabine in Treating Patients With T-cell Acute Lymphoblastic Leukemia or Lymphoblastic Lymphoma
- NCT00932139 · 160 participants · NA
Effect of Electro-Acupuncture on Blood Pressure
- NCT00992901 · 160 participants · Early Phase 1
Role of Neural and Hormonal Regulation Factors on Insulin Secretion After Gastric Bypass Surgery
- NCT01515527 · 160 participants · Phase 2
Cladribine Plus Low Dose Cytarabine (LDAC) Alternating With Decitabine in Patients With Acute Myeloid Leukemia (AML) or High-Risk Myelodysplastic Syndrome (MDS)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI